{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:34:29Z","timestamp":1792550069875,"version":"4.5.0"},"reference-count":197,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Among all clinical manifestations of pulmonary aspergillosis, invasive pulmonary aspergillosis (IPA) is the most acute presentation. IPA is caused by Aspergillus hyphae invading the pulmonary tissue, causing either tracheobronchitis and\/or bronchopneumonia. The degree of fungal invasion into the respiratory tissue can be seen as a spectrum, going from colonization to deep tissue penetration with angio-invasion, and largely depends on the host's immune status. Patients with prolonged, severe neutropenia and patients with graft-versus-host disease are at particularly high risk. However, IPA also occurs in other groups of immunocompromised and nonimmunocompromised patients, like solid organ transplant recipients or critically ill patients with severe viral disease. While a diagnosis of proven IPA is challenging and often warranted by safety and feasibility, physicians must rely on a combination of clinical, radiological, and mycological features to assess the likelihood for the presence of IPA. Triazoles are the first-choice regimen, and the choice of the drug should be made on an individual basis. Adjunctive therapy such as immunomodulatory treatment should also be taken into account. Despite an improving and evolving diagnostic and therapeutic armamentarium, the burden and mortality of IPA still remains high. This review aims to give a comprehensive and didactic overview of the current knowledge and best practices regarding the epidemiology, clinical presentation, diagnosis, and treatment of acute IPA.<\/jats:p>","DOI":"10.1055\/s-0043-1777769","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T19:15:16Z","timestamp":1705000516000},"page":"069-087","source":"Crossref","is-referenced-by-count":32,"title":["Acute Invasive Pulmonary Aspergillosis: Clinical Presentation and Treatment"],"prefix":"10.1055","volume":"45","author":[{"given":"Jannes","family":"Heylen","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Vanbiervliet","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium"},{"name":"Department of Haematology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium"},{"name":"Department of Haematology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Rijnders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrmicro.2017.90","article-title":"Aspergillus fumigatus morphology and dynamic host interactions","volume":"15","author":"F L van de Veerdonk","year":"2017","journal-title":"Nat Rev Microbiol"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"J P Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/505870","article-title":"Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey","volume":"43","author":"A Cornillet","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc4823","article-title":"Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients","volume":"10","author":"K H Vandewoude","year":"2006","journal-title":"Crit Care"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.200401-093OC","article-title":"Invasive aspergillosis in critically ill patients without malignancy","volume":"170","author":"W Meersseman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2334-13-29","article-title":"Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes","volume":"13","author":"J W Baddley","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13054-014-0722-7","article-title":"Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes","volume":"19","author":"F S Taccone","year":"2015","journal-title":"Crit Care"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1183\/09031936.00062206","article-title":"Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease","volume":"30","author":"P Bulpa","year":"2007","journal-title":"Eur Respir J"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/myc.13403","article-title":"Invasive fungal infections in acute and chronic liver impairment: a systematic review","volume":"65","author":"T Lahmer","year":"2022","journal-title":"Mycoses"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","article-title":"Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study","volume":"38","author":"J Wauters","year":"2012","journal-title":"Intensive Care Med"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study","volume":"6","author":"A FAD Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2213-2600(21)00442-2","article-title":"Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study","volume":"10","author":"J P Gangneux","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cmi.2021.08.014","article-title":"Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology","volume":"28","author":"J Prattes","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3201\/eid2711.211174","article-title":"Multinational observational cohort study of COVID-19-associated pulmonary aspergillosis","volume":"27","author":"N AF Janssen","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"myab064","DOI":"10.1093\/mmy\/myab064","article-title":"Aspergillosis: emerging risk groups in critically ill patients","volume":"60","author":"S Kluge","year":"2021","journal-title":"Med Mycol"},{"issue":"165","key":"ref16","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"G D Brown","year":"2012","journal-title":"Sci Transl Med"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"F Bongomin","year":"2017","journal-title":"J Fungi (Basel)"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"S Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"B De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1128\/CMR.12.2.310","article-title":"Aspergillus fumigatus and aspergillosis","volume":"12","author":"J-P Latg\u00e9","year":"1999","journal-title":"Clin Microbiol Rev"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-100-3-345","article-title":"Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia","volume":"100","author":"S L Gerson","year":"1984","journal-title":"Ann Intern Med"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/516480","article-title":"Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation","volume":"175","author":"A Wald","year":"1997","journal-title":"J Infect Dis"},{"issue":"13","key":"ref24","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"K A Marr","year":"2002","journal-title":"Blood"},{"issue":"08","key":"ref25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.bmt.1700737","article-title":"Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients","volume":"19","author":"E Jantunen","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"08","key":"ref26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"D P Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0163-4453(98)80173-4","article-title":"An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome","volume":"37","author":"D W Denning","year":"1998","journal-title":"J Infect"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"S J Lin","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1439-0507.2011.02044.x","article-title":"Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008)","volume":"55","author":"A M Tortorano","year":"2012","journal-title":"Mycoses"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13054-020-2808-8","article-title":"International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe","volume":"24","author":"K Thevissen","year":"2020","journal-title":"Crit Care"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4065\/75.6.562","article-title":"Comparison of premortem clinical diagnoses in critically ill patients and subsequent autopsy findings","volume":"75","author":"J Roosen","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/bmjqs-2012-000803","article-title":"Diagnostic errors in the intensive care unit: a systematic review of autopsy studies","volume":"21","author":"B Winters","year":"2012","journal-title":"BMJ Qual Saf"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1164\/rccm.202208-1570OC","article-title":"A pathology-based case series of influenza- and COVID-19-associated pulmonary aspergillosis: the proof is in the tissue","volume":"208","author":"L Vanderbeke","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"08","key":"ref34","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/myc.12927","article-title":"Invasive aspergillosis in critically ill patients: an autopsy study","volume":"62","author":"E E Tejerina","year":"2019","journal-title":"Mycoses"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"106720","DOI":"10.1016\/j.rmed.2021.106720","article-title":"Mortality outcomes associated with invasive aspergillosis among acute exacerbation of chronic obstructive pulmonary disease patient population","volume":"191","author":"T Mir","year":"2022","journal-title":"Respir Med"},{"issue":"07","key":"ref37","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1469-0691.2009.03015.x","article-title":"Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome","volume":"16","author":"J Guinea","year":"2010","journal-title":"Clin Microbiol Infect"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12890-020-01259-8","article-title":"The global impact of Aspergillus infection on COPD","volume":"20","author":"E E Hammond","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10096-017-2909-8","article-title":"Calling upon all public health mycologists : to accompany the country burden papers from 14 countries","volume":"36","author":"D W Denning","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"02","key":"ref40","first-page":"173","article-title":"Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient","volume":"26","author":"J Garnacho-Montero","year":"2013","journal-title":"Rev Esp Quimioter"},{"issue":"9398","key":"ref41","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","article-title":"Glucocorticoids and invasive fungal infections","volume":"362","author":"M S Lionakis","year":"2003","journal-title":"Lancet"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0953-6205(03)90006-9","article-title":"Inhaled corticosteroids in chronic obstructive pulmonary disease and disseminated aspergillosis","volume":"14","author":"R Barouky","year":"2003","journal-title":"Eur J Intern Med"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJM200008243430818","article-title":"Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone","volume":"343","author":"B A Leav","year":"2000","journal-title":"N Engl J Med"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1086\/341971","article-title":"Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy","volume":"35","author":"E Peter","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"1700532","DOI":"10.1183\/13993003.00532-2017","article-title":"Which algorithm diagnoses invasive pulmonary aspergillosis best in ICU patients with COPD?","volume":"50","author":"P Bulpa","year":"2017","journal-title":"Eur Respir J"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3111\/13696998.2011.564246","article-title":"US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host","volume":"14","author":"D A Patel","year":"2011","journal-title":"J Med Econ"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jinf.2012.07.006","article-title":"Clinical features of invasive pulmonary aspergillosis vs. colonization in COPD patients distributed by gold stage","volume":"65","author":"J Barberan","year":"2012","journal-title":"J Infect"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s13054-015-1140-1","article-title":"Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease: a matched cohort study","volume":"19","author":"C Delsuc","year":"2015","journal-title":"Crit Care"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance","volume":"61","author":"A Albillos","year":"2014","journal-title":"J Hepatol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fimmu.2019.00293","article-title":"Causes and consequences of innate immune dysfunction in cirrhosis","volume":"10","author":"K M Irvine","year":"2019","journal-title":"Front Immunol"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL clinical practice guidelines: management of alcohol-related liver disease","volume":"69","author":"M Thursz","year":"2018","journal-title":"J Hepatol"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/liv.13981","article-title":"Invasive fungal infections amongst patients with acute-on-chronic liver failure at high risk for fungal infections","volume":"39","author":"N Verma","year":"2019","journal-title":"Liver Int"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11046-014-9740-x","article-title":"Invasive mycosis in medical intensive care unit patients with severe alcoholic hepatitis","volume":"177","author":"T Lahmer","year":"2014","journal-title":"Mycopathologia"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jhep.2013.09.011","article-title":"Invasive aspergillosis in patients with severe alcoholic hepatitis","volume":"60","author":"T Gustot","year":"2014","journal-title":"J Hepatol"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13613-019-0502-2","article-title":"Invasive pulmonary aspergillosis in cirrhotic patients: analysis of a 10-year clinical experience","volume":"9","author":"E Levesque","year":"2019","journal-title":"Ann Intensive Care"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1586\/17476348.2015.996132","article-title":"Invasive pulmonary aspergillosis in patients with influenza infection: report of two cases and systematic review of the literature","volume":"9","author":"K Alshabani","year":"2015","journal-title":"Expert Rev Respir Med"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1164\/rccm.201612-2540LE","article-title":"Influenza-associated aspergillosis in critically ill patients","volume":"196","author":"F L van de Veerdonk","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00134-021-06431-0","article-title":"Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial","volume":"47","author":"L Vanderbeke","year":"2021","journal-title":"Intensive Care Med"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/myc.13410","article-title":"Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: a systematic review and meta-analysis","volume":"65","author":"C Shi","year":"2022","journal-title":"Mycoses"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/jof8010049","article-title":"Clinical and microbiological characteristics of culture-positive, influenza-associated pulmonary aspergillosis: a single-center study in southern Taiwan, 2016-2019","volume":"8","author":"C J Wu","year":"2022","journal-title":"J Fungi (Basel)"},{"issue":"07","key":"ref61","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/cid\/ciaa007","article-title":"High rates of influenza-associated invasive pulmonary aspergillosis may not be universal: a retrospective cohort study from Alberta, Canada","volume":"71","author":"I S Schwartz","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref62","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/CCM.0000000000004861","article-title":"The extent of aspergillosis in critically ill patients with severe influenza pneumonia: a multicenter cohort study","volume":"49","author":"A Coste","year":"2021","journal-title":"Crit Care Med"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00134-016-4578-y","article-title":"Increased incidence of co-infection in critically ill patients with influenza","volume":"43","author":"I Martin-Loeches","year":"2017","journal-title":"Intensive Care Med"},{"issue":"11","key":"ref64","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00134-021-06510-2","article-title":"COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges","volume":"47","author":"J Prattes","year":"2021","journal-title":"Intensive Care Med"},{"issue":"12","key":"ref65","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/jof7121067","article-title":"A visual and comprehensive review on COVID-19-associated pulmonary aspergillosis (CAPA)","volume":"7","author":"S Feys","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","article-title":"Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales","volume":"400","author":"U Agrawal","year":"2022","journal-title":"Lancet"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cid\/ciaa863","article-title":"COVID-19 in immunocompromised hosts: what we know so far","volume":"72","author":"M Fung","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref68","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamainternmed.2021.7024","article-title":"Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US","volume":"182","author":"J Sun","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"07","key":"ref70","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1093\/cid\/ciaa1298","article-title":"A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit","volume":"73","author":"P L White","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ref71","doi-asserted-by":"crossref","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","article-title":"Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study","volume":"73","author":"M Bartoletti","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"04","key":"ref72","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.healun.2011.01.701","article-title":"A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients","volume":"30","author":"S Husain","year":"2011","journal-title":"J Heart Lung Transplant"},{"issue":"05","key":"ref73","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1378\/chest.112.5.1160","article-title":"Aspergillus airway colonization and invasive disease after lung transplantation","volume":"112","author":"B C Cahill","year":"1997","journal-title":"Chest"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ajt.12115","article-title":"Aspergillosis in solid organ transplantation","volume":"13","author":"N Singh","year":"2013","journal-title":"Am J Transplant"},{"issue":"04","key":"ref75","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jinf.2012.07.008","article-title":"Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality","volume":"65","author":"T W Felton","year":"2012","journal-title":"J Infect"},{"issue":"05","key":"ref76","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1164\/rccm.201910-1931OC","article-title":"Invasive tracheobronchial aspergillosis in critically ill patients with severe influenza. a clinical trial","volume":"202","author":"R Nyga","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"07","key":"ref77","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S2213-2600(21)00138-7","article-title":"COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion","volume":"9","author":"F L van de Veerdonk","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"03","key":"ref78","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1053-2498(02)00477-1","article-title":"Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management","volume":"22","author":"N Singh","year":"2003","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"ref79","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.cmi.2019.04.031","article-title":"Intensive care management of influenza-associated pulmonary aspergillosis","volume":"25","author":"P Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"05","key":"ref80","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MD.0b013e31826c2ccf","article-title":"Aspergillus tracheobronchitis: report of 8 cases and review of the literature","volume":"91","author":"M Fern\u00e1ndez-Ruiz","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"04","key":"ref81","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/513943","article-title":"Invasive aspergillosis","volume":"26","author":"D W Denning","year":"1998","journal-title":"Clin Infect Dis"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"A J Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"04","key":"ref83","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"T F Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref84","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jinf.2011.08.007","article-title":"Computed tomography findings in invasive pulmonary aspergillosis in non-neutropenic transplant recipients and neutropenic patients, and their prognostic value","volume":"63","author":"S Y Park","year":"2011","journal-title":"J Infect"},{"key":"ref85","first-page":"231","article-title":"Pulmonary aspergillosis: pathologic and pathogenetic features","volume":"28","author":"R S Fraser","year":"1993","journal-title":"Pathol Annu"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/thx.43.2.108","article-title":"Apparent pulmonary mycetoma following invasive aspergillosis in neutropenic patients","volume":"43","author":"C C Kibbler","year":"1988","journal-title":"Thorax"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1148\/radiographics.8.1.3353534","article-title":"High resolution CT of the lung parenchyma with pathologic correlation","volume":"8","author":"M A Meziane","year":"1988","journal-title":"Radiographics"},{"issue":"07","key":"ref88","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/thx.37.7.554","article-title":"The air crescent sign of invasive pulmonary aspergillosis in acute leukaemia","volume":"37","author":"M L Slevin","year":"1982","journal-title":"Thorax"},{"issue":"04","key":"ref89","first-page":"332","article-title":"Invasive aspergillosis in a \u201chealthy\u201d patient","volume":"131","author":"K J Ascah","year":"1984","journal-title":"Can Med Assoc J"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"20170220","DOI":"10.1259\/bjr.20170220","article-title":"The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies","volume":"91","author":"C Sassi","year":"2018","journal-title":"Br J Radiol"},{"issue":"02","key":"ref91","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2214\/AJR.05.0513","article-title":"Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome","volume":"187","author":"H Brodoefel","year":"2006","journal-title":"AJR Am J Roentgenol"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","article-title":"Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia","volume":"19","author":"D Caillot","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/cid\/ciaa1855","article-title":"Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis: from the Imaging Working Group for the Revision and Update of the Consensus Definitions of Fungal Disease from the EORTC\/MSGERC","volume":"72","author":"B D Alexander","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"08","key":"ref94","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(22)00166-1","article-title":"[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"9","author":"A Douglas","year":"2022","journal-title":"Lancet Haematol"},{"issue":"05","key":"ref95","first-page":"2999","article-title":"18F-FDG-PET\/CT imaging in patients with febrile neutropenia and haematological malignancies","volume":"35","author":"V Camus","year":"2015","journal-title":"Anticancer Res"},{"issue":"06","key":"ref96","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jcrc.2014.06.006","article-title":"Safety of research bronchoscopy in critically ill patients","volume":"29","author":"S EW Prebil","year":"2014","journal-title":"J Crit Care"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imj.15591","article-title":"Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021","volume":"51","author":"A P Douglas","year":"2021","journal-title":"Intern Med J"},{"issue":"01","key":"ref98","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1086\/524076","article-title":"Manual of Clinical Microbiology, 9th Edition Edited by Patrick R. Murray, Ellen Jo Baron, James H. Jorgensen, Marie Louise Landry, and Michael A. Pfaller Washington, DC: ASM Press, 2007 2488 pp., illustrated. $209.95 (hardcover)","volume":"46","author":"G P Wormser","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref99","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2141.2001.02901.x","article-title":"Clinical significance of Aspergillus fungaemia in patients with haematological malignancies and invasive aspergillosis","volume":"114","author":"C Girmenia","year":"2001","journal-title":"Br J Haematol"},{"issue":"06","key":"ref100","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"P Koehler","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"04","key":"ref101","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/myc.13216","article-title":"Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis","volume":"64","author":"C M Roman-Montes","year":"2021","journal-title":"Mycoses"},{"issue":"08","key":"ref102","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00134-021-06449-4","article-title":"Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis","volume":"47","author":"P E Verweij","year":"2021","journal-title":"Intensive Care Med"},{"issue":"05","key":"ref103","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/MCC.0000000000000637","article-title":"Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together","volume":"25","author":"S Blot","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1093\/cid\/ciaa1786","article-title":"Defining galactomannan positivity in the updated EORTC\/MSGERC consensus definitions of invasive fungal diseases","volume":"72","author":"T Mercier","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1164\/rccm.200704-606OC","article-title":"Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients","volume":"177","author":"W Meersseman","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"ref106","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1128\/CVI.00226-08","article-title":"Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid","volume":"15","author":"S Husain","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"ref107","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1128\/JCM.42.12.5517-5522.2004","article-title":"Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid","volume":"42","author":"B Musher","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"11","key":"ref108","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1086\/647935","article-title":"Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases","volume":"49","author":"J Maertens","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"04","key":"ref109","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1128\/JCM.06423-11","article-title":"Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity","volume":"50","author":"J D'Haese","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"08","key":"ref110","doi-asserted-by":"crossref","first-page":"e43347","DOI":"10.1371\/journal.pone.0043347","article-title":"Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis","volume":"7","author":"M Zou","year":"2012","journal-title":"PLoS One"},{"issue":"04","key":"ref111","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1378\/chest.10-0488","article-title":"Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review","volume":"138","author":"Y L Guo","year":"2010","journal-title":"Chest"},{"issue":"01","key":"ref112","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/1040841X.2013.804033","article-title":"Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis","volume":"41","author":"S C Heng","year":"2015","journal-title":"Crit Rev Microbiol"},{"issue":"10","key":"ref113","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis","volume":"42","author":"C D Pfeiffer","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref114","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1469-0691.2008.02122.x","article-title":"Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis","volume":"15","author":"C Cordonnier","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"03","key":"ref115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5603\/AIT.2014.0027","article-title":"Prognostic value of serum galactomannan in mixed ICU patients: a retrospective observational study","volume":"46","author":"S Teering","year":"2014","journal-title":"Anaesthesiol Intensive Ther"},{"issue":"06","key":"ref116","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood.V97.6.1604","article-title":"Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation","volume":"97","author":"J Maertens","year":"2001","journal-title":"Blood"},{"issue":"12","key":"ref117","first-page":"CD007394","article-title":"Galactomannan detection for invasive aspergillosis in immunocompromised patients","volume":"2015","author":"M M Leeflang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"08","key":"ref118","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/civ555","article-title":"Galactomannan and polymerase chain reaction-based screening for invasive aspergillosis among high-risk hematology patients: a diagnostic meta-analysis","volume":"61","author":"M Arvanitis","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"12","key":"ref119","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/cid\/ciu673","article-title":"Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis","volume":"59","author":"R F Duarte","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"05","key":"ref120","doi-asserted-by":"crossref","first-page":"e0004423","DOI":"10.1128\/jcm.00044-23","article-title":"Retrospective multicenter evaluation of the VirClia galactomannan antigen assay for the diagnosis of pulmonary aspergillosis with bronchoalveolar lavage fluid samples from patients with hematological disease","volume":"61","author":"J B Buil","year":"2023","journal-title":"J Clin Microbiol"},{"issue":"02","key":"ref121","doi-asserted-by":"crossref","first-page":"e0262621","DOI":"10.1128\/spectrum.02626-21","article-title":"Comparison of the performance of two galactomannan detection tests: platelia aspergillus ag and aspergillus galactomannan Ag Virclia monotest","volume":"10","author":"A L Calero","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"07","key":"ref122","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1128\/JCM.03567-13","article-title":"Use and limits of (1-3)-\u03b2-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis","volume":"52","author":"A Sulahian","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"10","key":"ref123","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1128\/AAC.00658-06","article-title":"Reactivity of (1\u2013>3)-\u03b2-d-glucan assay with commonly used intravenous antimicrobials","volume":"50","author":"F M Marty","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref124","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/jac\/dkw323","article-title":"PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay\u00ae in 201 patients with haematological disease suspected for invasive aspergillosis","volume":"71","author":"G M Chong","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"06","key":"ref125","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1128\/JCM.39.6.2338-2340.2001","article-title":"Detection of Aspergillus species DNA by PCR in bronchoalveolar lavage fluid","volume":"39","author":"M P Hayette","year":"2001","journal-title":"J Clin Microbiol"},{"issue":"02","key":"ref126","first-page":"89","article-title":"A systematic literature review on the diagnosis of invasive aspergillosis using polymerase chain reaction (PCR) from bronchoalveolar lavage clinical samples","volume":"24","author":"F F Tuon","year":"2007","journal-title":"Rev Iberoam Micol"},{"issue":"11","key":"ref127","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1128\/JCM.00942-12","article-title":"Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review","volume":"50","author":"T Avni","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"12","key":"ref128","doi-asserted-by":"crossref","first-page":"e28467","DOI":"10.1371\/journal.pone.0028467","article-title":"Evaluation of PCR on bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis: a bivariate metaanalysis and systematic review","volume":"6","author":"W Sun","year":"2011","journal-title":"PLoS One"},{"issue":"01","key":"ref129","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/cid\/ciad141","article-title":"Clinical impact of polymerase chain reaction-based aspergillus and azole resistance detection in invasive aspergillosis: a prospective multicenter study","volume":"77","author":"S Huygens","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"10","key":"ref130","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1128\/JCM.01365-14","article-title":"PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance","volume":"52","author":"M Arvanitis","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"04","key":"ref131","first-page":"402","article-title":"Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What is Aspergillus?","volume":"55","author":"C O Morton","year":"2017","journal-title":"Med Mycol"},{"issue":"11","key":"ref132","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1128\/JCM.05316-11","article-title":"Evaluation of Aspergillus PCR protocols for testing serum specimens","volume":"49","author":"P L White","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"04","key":"ref133","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bjh.12285","article-title":"Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies","volume":"161","author":"T R Rogers","year":"2013","journal-title":"Br J Haematol"},{"issue":"03","key":"ref134","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/ciu833","article-title":"Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial","volume":"60","author":"J M Aguado","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"03","key":"ref135","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/jac\/dkaa498","article-title":"The impact of anti-mould prophylaxis on Aspergillus PCR blood testing for the diagnosis of invasive aspergillosis","volume":"76","author":"M Cruciani","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"04","key":"ref136","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/jof6040216","article-title":"Diagnosis of breakthrough fungal infections in the clinical mycology laboratory: an ECMM consensus statement","volume":"6","author":"J D Jenks","year":"2020","journal-title":"J Fungi (Basel)"},{"issue":"01","key":"ref137","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","article-title":"A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients","volume":"186","author":"S I Blot","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"08","key":"ref138","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00134-020-06091-6","article-title":"Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion","volume":"46","author":"P E Verweij","year":"2020","journal-title":"Intensive Care Med"},{"issue":"02","key":"ref139","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/S2666-5247(20)30027-6","article-title":"Diagnosing COVID-19-associated pulmonary aspergillosis","volume":"1","author":"P E Verweij","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1093\/cid\/ciaa1751","article-title":"EORTC\/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group","volume":"72","author":"M Bassetti","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"05","key":"ref141","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MCC.0000000000001070","article-title":"Invasive pulmonary aspergillosis in the ICU: tale of a broadening risk profile","volume":"29","author":"D Koulenti","year":"2023","journal-title":"Curr Opin Crit Care"},{"issue":"11","key":"ref142","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/apm.13316","article-title":"Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices","volume":"131","author":"S Gaffney","year":"2023","journal-title":"APMIS"},{"issue":"03","key":"ref143","doi-asserted-by":"crossref","first-page":"e0216921","DOI":"10.1128\/jcm.02169-21","article-title":"Combination of mycological criteria: a better surrogate to identify COVID-19-associated pulmonary aspergillosis patients and evaluate prognosis?","volume":"60","author":"S Delli\u00e8re","year":"2022","journal-title":"J Clin Microbiol"},{"issue":"05","key":"ref144","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jinf.2022.08.003","article-title":"Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: an update including COVID-19 data","volume":"85","author":"M Bassetti","year":"2022","journal-title":"J Infect"},{"issue":"04","key":"ref145","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/myc.12869","article-title":"Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project","volume":"62","author":"M Bassetti","year":"2019","journal-title":"Mycoses"},{"issue":"03","key":"ref146","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/jof4030098","article-title":"Treatment of aspergillosis","volume":"4","author":"J D Jenks","year":"2018","journal-title":"J Fungi (Basel)"},{"issue":"03","key":"ref147","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"F Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"J A Maertens","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"ref149","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"O A Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/jof7020076","article-title":"Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients","volume":"7","author":"M E Klatt","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"12","key":"ref151","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"D Zonios","year":"2014","journal-title":"J Infect Dis"},{"issue":"08","key":"ref152","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse effects associated with long-term administration of azole antifungal agents","volume":"79","author":"L L Benitez","year":"2019","journal-title":"Drugs"},{"issue":"09","key":"ref153","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/myc.12960","article-title":"Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology","volume":"62","author":"O A Cornely","year":"2019","journal-title":"Mycoses"},{"issue":"02","key":"ref154","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jinf.2020.05.051","article-title":"Evaluation of MucorGenius\u00ae mucorales PCR assay for the diagnosis of pulmonary mucormycosis","volume":"81","author":"H Guegan","year":"2020","journal-title":"J Infect"},{"issue":"04","key":"ref155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3324\/haematol.2012.065110","article-title":"Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)","volume":"98","author":"A Skiada","year":"2013","journal-title":"Haematologica"},{"issue":"09","key":"ref156","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"P P Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"05","key":"ref157","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/cid\/ciab1066","article-title":"Evaluation of serum mucorales polymerase chain reaction (PCR) for the diagnosis of mucormycoses: the MODIMUCOR prospective trial","volume":"75","author":"L Millon","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ref158","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1086\/508455","article-title":"Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection","volume":"43","author":"N G Almyroudis","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1086\/430921","article-title":"Salvage therapy for aspergillosis","volume":"41","author":"J E Bennett","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"K A Marr","year":"2015","journal-title":"Ann Intern Med"},{"issue":"11","key":"ref161","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"J Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref162","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"T J Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"21","key":"ref163","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"N M Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref164","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/jac\/dki252","article-title":"Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF","volume":"56","author":"E Sionov","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"06","key":"ref165","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1189\/jlb.70.6.868","article-title":"In vivo GM-CSF prevents dexamethasone suppression of killing of Aspergillus fumigatus conidia by bronchoalveolar macrophages","volume":"70","author":"E Brummer","year":"2001","journal-title":"J Leukoc Biol"},{"issue":"18","key":"ref166","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1182\/blood-2015-05-645986","article-title":"Efficacy of transfusion with granulocytes from G-CSF\/dexamethasone-treated donors in neutropenic patients with infection","volume":"126","author":"T H Price","year":"2015","journal-title":"Blood"},{"issue":"20","key":"ref167","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM198105143042001","article-title":"Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions","volume":"304","author":"D G Wright","year":"1981","journal-title":"N Engl J Med"},{"issue":"05","key":"ref168","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10875-022-01261-1","article-title":"Granulocyte transfusions in patients with chronic granulomatous disease undergoing hematopoietic cell transplantation or gene therapy","volume":"42","author":"D E Arnold","year":"2022","journal-title":"J Clin Immunol"},{"issue":"12","key":"ref169","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S1470-2045(17)30852-5","article-title":"Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis","volume":"18","author":"N Daver","year":"2017","journal-title":"Lancet Oncol"},{"issue":"08","key":"ref170","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJM199102213240801","article-title":"A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease","volume":"324","author":"International Chronic Granulomatous Disease Cooperative Study Group","year":"1991","journal-title":"N Engl J Med"},{"issue":"01","key":"ref171","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cncr.21142","article-title":"Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia","volume":"104","author":"M C Dignani","year":"2005","journal-title":"Cancer"},{"issue":"12","key":"ref172","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"J A Maertens","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"03","key":"ref173","doi-asserted-by":"crossref","first-page":"e13832","DOI":"10.1111\/tid.13832","article-title":"Antifungal prophylaxis in adult lung transplant recipients: Uncertainty despite 30 years of experience. A systematic review of the literature and network meta-analysis","volume":"24","author":"T Marinelli","year":"2022","journal-title":"Transpl Infect Dis"},{"issue":"04","key":"ref174","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"O A Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"04","key":"ref175","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"A J Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"e14162","DOI":"10.1111\/tid.14162","article-title":"Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients","volume":"e14162","author":"A M Khatri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients","volume":"86","author":"EORTC International Antimicrobial Therapy Cooperative Group","year":"1989","journal-title":"Am J Med"},{"issue":"15","key":"ref179","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2008.06.040","article-title":"Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis","volume":"44","author":"E Goldberg","year":"2008","journal-title":"Eur J Cancer"},{"issue":"08","key":"ref180","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"C Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"04","key":"ref181","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2009.21.8032","article-title":"Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study","volume":"28","author":"C Girmenia","year":"2010","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref182","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3324\/haematol.2011.042598","article-title":"The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project","volume":"96","author":"L Pagano","year":"2011","journal-title":"Haematologica"},{"issue":"09","key":"ref183","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"J Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ref184","first-page":"CD013604","article-title":"Pre-emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer","volume":"11","author":"Y Uneno","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"04","key":"ref185","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/cid\/ciac623","article-title":"Empiric vs preemptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the European Organization for Research and Treatment of Cancer","volume":"76","author":"J Maertens","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref186","doi-asserted-by":"crossref","first-page":"e65776","DOI":"10.1371\/journal.pone.0065776","article-title":"Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model","volume":"8","author":"M Schwarzinger","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"ref187","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.020073","article-title":"Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study","volume":"95","author":"C Cordonnier","year":"2010","journal-title":"Haematologica"},{"issue":"03","key":"ref188","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bmt.1705720","article-title":"Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and\/or systemic fungal infection","volume":"40","author":"P de Fabritiis","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"02","key":"ref189","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000083447","article-title":"Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B","volume":"113","author":"W H Kr\u00fcger","year":"2005","journal-title":"Acta Haematol"},{"issue":"05","key":"ref190","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"B H Segal","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref191","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/jac\/dkab317","article-title":"When to change treatment of acute invasive aspergillosis: an expert viewpoint","volume":"77","author":"M A Slavin","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"08","key":"ref192","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1007\/s00330-016-4717-4","article-title":"Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis","volume":"27","author":"J J Vehreschild","year":"2017","journal-title":"Eur Radiol"},{"issue":"01","key":"ref193","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.22738","article-title":"Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications","volume":"110","author":"M H Miceli","year":"2007","journal-title":"Cancer"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fmicb.2018.00661","article-title":"Galactomannan, a surrogate marker for outcome in invasive aspergillosis: finally coming of age","volume":"9","author":"T Mercier","year":"2018","journal-title":"Front Microbiol"},{"issue":"02","key":"ref195","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/jcm9020610","article-title":"A mortality prediction rule for hematology patients with invasive aspergillosis based on serum galactomannan kinetics","volume":"9","author":"T Mercier","year":"2020","journal-title":"J Clin Med"},{"issue":"07","key":"ref196","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1128\/JCM.06513-11","article-title":"Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis","volume":"50","author":"L YA Chai","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"04","key":"ref197","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/JCM.02281-09","article-title":"Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis","volume":"48","author":"S Koo","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"06","key":"ref198","doi-asserted-by":"crossref","first-page":"e0129022","DOI":"10.1371\/journal.pone.0129022","article-title":"Correlation between circulating fungal biomarkers and clinical outcome in invasive aspergillosis","volume":"10","author":"D Neofytos","year":"2015","journal-title":"PLoS One"},{"issue":"07","key":"ref199","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/339324","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease","volume":"34","author":"F Boutboul","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cncr.24022","article-title":"Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients","volume":"115","author":"J Maertens","year":"2009","journal-title":"Cancer"},{"issue":"06","key":"ref201","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.patbio.2011.10.011","article-title":"Clinical utility and prognostic value of galactomannan in neutropenic patients with invasive aspergillosis","volume":"60","author":"I Hadrich","year":"2012","journal-title":"Pathol Biol (Paris)"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1777769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:19:54Z","timestamp":1730809194000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1777769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":197,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,1,29]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1777769","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}